Cowen Raises Price Target on Momenta Phama (MNTA) Following 2Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Momenta Pharmaceuticals Reports Second Quarter 2015 Financial Results
August 4, 2015 8:00 AM EDT--Launch of GlatopaTM drives second quarter revenue growth--
--Company strengthens balance sheet through ~$150 million equity financing--
CAMBRIDGE, Mass., Aug. 04, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the second quarter ended June 30, 2015.
For the second quarter of 2015, the Company reported total revenues of $44.9 million, consisting primarily of product and milestone revenues relating to the approval and launch of GlatopaTM (glatiramer acetate injection). Momenta reported a net loss of $(2.2) million, or $(0.04) per... More
